WEBULL
WebtradeDownload

Recursion Pharmaceuticals (RXRX) Could Be 95% Overvalued As Estimate Cuts Pressure Shares

Simply Wall St · 1d ago

Recursion Pharmaceuticals (RXRX) drew attention after the share price declined 8.03% to close at US$4.01, as recent downward earnings estimate revisions and a Sell rating weighed on sentiment.

Recent moves paint a mixed picture for Recursion Pharmaceuticals. The share price is down 4.36% over the last session and 17.17% over the past week, yet the 30 day and 90 day share price returns of 19.84% and 15.86% point to earlier momentum that is now fading as analysts reassess earnings risk. Over a longer horizon, the pressure is clearer, with total shareholder return down 8.69% year to date and 34.89% over one year, as well as declines of 41.18% over three years and 80.55% over five years.

Balance recent volatility in Recursion Pharmaceuticals with a curated set of alternatives by reviewing 33 healthcare AI stocks that share the same blend of biotech and AI-driven drug discovery.

After an 8% single day drop and years of weak total returns, Recursion Pharmaceuticals now trades at a level where sentiment is poor and analyst targets sit higher. The question is whether the current price still offers enough potential upside to justify the risk.

Most Popular Narrative: 95% Overvalued

Based on the most followed narrative, Recursion Pharmaceuticals is seen as trading well above a suggested fair value of $1.97 compared with the recent close near $3.84, which frames current enthusiasm as too rich for the fundamentals described in that view.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

See why 17 investors see Recursion Pharmaceuticals as 95% overvalued.

Result: Fair Value of $1.97 (OVERVALUED)

Still, Recursion Pharmaceuticals faces two clear risks that could flip this bearish narrative if clinical data yield positive surprises or if collaboration partners deepen their commitments.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another View on Recursion Pharmaceuticals' Valuation

The community narrative calls Recursion Pharmaceuticals overvalued at a fair value of $1.97, yet our DCF model points the other way. On that framework, RXRX at about $3.84 screens as undervalued against an estimated future cash flow value of $9.66. Which story do you trust more: the crowd or the cash flows?

Before leaning on either signal, it helps to see how that cash flow approach is built in practice. Look into how the SWS DCF model arrives at its fair value.

RXRX Discounted Cash Flow as at Oct 2026
RXRX Discounted Cash Flow as at Oct 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Recursion Pharmaceuticals is clearly split, so use that tension as a prompt to review the data yourself and move quickly while information is fresh. To see the full mix of concerns and potential upsides that other investors are focused on, start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Recursion Pharmaceuticals?

If Recursion Pharmaceuticals has you thinking harder about risk and reward, do not stop here. Use the data to your advantage and line up a stronger watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.